GLP‑1s and body composition
- An International Journal of Obesity meta-analysis published April 25 found glucagon-like peptide-1 drugs mostly cut fat mass, while Hone Health’s April 14 BodySpec deal turned that body-composition tracking into a clinical product. - The review covered 36 studies, with 24 pooled in meta-analysis, and reported about 9% weight loss at three months; across studies, lean-mass reductions were modest while fat loss dominated. - With roughly 12% of U.S. adults estimated to be taking GLP-1 drugs, providers are starting to treat the scale as an incomplete readout. (medcitynews.com)
GLP-1 drugs lower body weight, but a new April 25 meta-analysis says the bigger question is what kind of tissue patients are losing. (nature.com) The paper, published in the International Journal of Obesity, reviewed 36 studies and pooled 24 in a meta-analysis of glucagon-like peptide-1 receptor agonists and dual GLP-1/GIP drugs in adults with overweight or obesity, with or without type 2 diabetes. (nature.com) Across those studies, the drugs reduced body weight, body mass index and waist circumference at 3, 6 and 12 months. At three months, mean body weight fell about 9%, and the drop came with marked reductions in fat mass and visceral adipose tissue, the fat packed around internal organs. (nature.com) At six months, average weight reduction was about 5%, and the authors said lean mass was largely preserved. At 12 months, weight loss remained around 4%, with more variation between drugs, especially liraglutide. (nature.com) That distinction matters because a bathroom scale adds fat, muscle, water and bone into one number. A body-composition scan separates those compartments, showing whether a patient is losing fat, muscle or bone density. (honehealth.com) Hone Health moved on that idea on April 14, announcing a partnership with BodySpec to offer dual-energy X-ray absorptiometry, or DEXA, scans inside its telehealth platform. Patients can buy a scan in the Hone app, complete it at a BodySpec site, and have a clinician fold the results into a care plan. (honehealth.com) (mobihealthnews.com) BodySpec says its scans measure lean muscle mass, visceral fat, bone density, resting metabolic rate, and total and regional body fat. Hone founder and chief executive Saad Alam said those data can show whether a patient is losing fat, gaining muscle or losing bone density. (honehealth.com) (mobihealthnews.com) MedCity News reported April 24 that the partnership is aimed directly at patients using GLP-1 drugs, not just general longevity tracking. BodySpec chief executive Elaine Shi told the outlet that a home scale is a “very blunt instrument” because it cannot show whether weight loss came from fat or lean muscle. (medcitynews.com) The backdrop is rapid adoption. MedCity cited an estimate that about 12% of U.S. adults are now taking GLP-1 medications, pushing more providers to ask whether weight alone is an adequate measure of success. (medcitynews.com) The new paper does not say muscle loss never happens. Its conclusion is narrower: across the studies it reviewed, GLP-1 therapies produced clinically meaningful weight loss “primarily through selective fat mass reduction,” while nutritional support and exercise still mattered for long-term outcomes. (nature.com) The result is a shift in what gets tracked. As GLP-1 care spreads, the headline number is moving from pounds lost to the split between fat lost and lean tissue preserved. (nature.com) (medcitynews.com)
